Under the agreement, both the parties are expected to leverage their capabilities for supporting the development of TB vaccines.
The scope of potential activities will cover the full spectrum of product development, including pre-clinical development, process development and manufacturing, and clinical development in TB and potentially other disease areas.
Aeras president and CEO Jim Connolly said this new collaboration will bring more opportunities to both organizations in pursuing greater innovation and building increased technical capacity for vaccine development.